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Abstract
A woman presented at age 18 years with partial myelitis and diplopia and experienced multiple
subsequent relapses. Her MRI demonstrated T2 abnormalities characteristic of multiple sclerosis
(MS) (white matter ovoid lesions and Dawson ﬁngers), and CSF demonstrated an elevated IgG
index and oligoclonal bands restricted to the CSF. Diagnosed with clinically deﬁnite relapsingremitting MS, she was treated with various MS disease-modifying therapies and eventually began
experiencing secondary progression. At age 57 years, she developed an acute longitudinally
extensive transverse myelitis and was found to have AQP4 antibodies by cell-based assay. Our
analysis of the clinical course, radiographic ﬁndings, molecular diagnostic methods, and treatment
response characteristics support the hypothesis that our patient most likely had 2 CNS inﬂammatory disorders: MS, which manifested as a teenager, and neuromyelitis optica spectrum
disorder, which evolved in her sixth decade of life. This case emphasizes a key principle in
neurology practice, which is to reconsider whether the original working diagnosis remains tenable, especially when confronted with evidence (clinical and/or paraclinical) that raises the
possibility of a distinctively diﬀerent disorder.
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Glossary
DMT = disease-modifying therapy; MS = multiple sclerosis; NMOSD = neuromyelitis optica spectrum disorder; RRMS =
relapsing-remitting MS; S-1-P = sphingosine-1-phosphate; SPMS = secondary progressive MS; UTI = urinary tract infection.

Case Presentation
The patient is a 57-year-old woman followed at our comprehensive multiple sclerosis (MS) center at the Cleveland Clinic
after decades with the diagnosis of clinically deﬁnite, relapsingremitting MS (RRMS), followed by a transition to secondary
progressive MS (SPMS), who now presents with longitudinally
extensive transverse myelitis. The inception of this patient’s
neurologic course began in 1981 at age 18 years with partial
transverse myelitis, followed by an episode of double vision
(Figure 1). Following corticosteroid therapy, she recovered
completely from both syndromes, and a diagnosis of clinically
deﬁnite RRMS was established. She was later treated with interferon beta-1a and remained neurologically stable on this
therapy for nearly 3 decades until 2009 at which time a new
clinical relapse prompted the transition of her diseasemodifying therapy (DMT) to glatiramer acetate (Figure 1).
Although she remained stable on glatiramer acetate with no evidence of disease activity for approximately 10 years, a follow-up
visit in May 2019 revealed worsening on tests of processing speed,

timed 25-foot walk, and fatigue. A surveillance brain MRI at that
time showed lesions highly characteristic for MS (ovoids, Dawson
ﬁngers, periventricular plaques, and lesions perpendicular to the
long axis of the ventricles) and multiple new and/or enlarging T2
hyperintense nonenhancing lesions in the deep white matter
when compared with a February 2017 scan (Figure 2). Her
course at that time was most consistent with SPMS.
In November of the same year, the patient developed the subacute onset of bilateral lower extremity weakness, rendering her
nonambulatory and requiring the use of a wheelchair (Expanded
Disability Status Scale score of 7). Examination at that time
revealed full strength in the upper extremities, decreased
strength in the lower extremities (rated 3 on the Medical Research Council scale), diminished sensation to vibration that
was worse on the left vs the right lower extremity, diﬀusely brisk
reﬂexes without clonus, and ﬁnger-to-nose dysmetria. Following
high-dose oral prednisone treatment, she once again exhibited
signiﬁcant improvement and was able to ambulate with a walker.
By February 2020, the patient was transitioned to siponimod, an
oral sphingosine-1-phosphate (S-1-P) receptor modulator.

Figure 1 Chronological Heat Map

In this figure, we detail the condition of the patient over time. The longitudinal axis (left to right) depicts the condition of the disease, whereas the smaller
amplitude and lighter color indicates greater stability of the disease. Alternately, the expanded amplitude of the colored heat map (above and below the
horizontal linear axis over time) designates increased disease activity (whether on a clinical or paraclinical basis) or complications of the treatment of disease.
Other fields of information are added either above or below the heat map and include information about treatments, diagnoses, commentaries adding
contextual perspectives, and results from specific test assessments from each most relevant period of clinical decision making. Each field is consistently color
coded throughout as defined in the figure legend.16
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Figure 2 May 2019 Brain MRI

Axial and sagittal fluid attenuated inversion recovery imaging showing (A) juxtacortical, (B) periventricular, (C) infratentorial affecting the cerebral peduncles,
(D/E) classic Dawson fingers and hyperintensities in a pattern that is typical of multiple sclerosis (arrows).

One month following the transition to siponimod, she
reported diﬃculty ambulating, generalized weakness, dizziness, dysarthria, worsening spasticity, and confusion. Brain
MRI showed greater than multiple new enhancing brain lesions, most prominently in the right centrum semiovale, anterior to the right lateral ventricle, and in the right superior
periventricular region (Figure 3). She was treated with highdose steroids and antibiotics for a concomitant urinary tract
infection (UTI).
Two months later, she described the new onset of weakness in
the left upper extremity, which was conﬁrmed on examination, in conjunction with nonsustained ankle clonus bilaterally. Siponimod was held due to lymphopenia at 200
cells/μL.
She then presented to the emergency department with diﬃculty ambulating and altered mental status. A brain MRI
showed no abnormal enhancements and no evidence of acute
ischemia. MRI of the cervical and thoracic spine showed
discontinuous short-segment (i.e., skip) nonenhancing lesions. She was treated with high-dose corticosteroids and
antibiotics for yet another UTI, improved, and was subsequently discharged home. However, 1 week later, the patient was admitted to the hospital for worsening gait,
dysphagia, and diﬀuse weakness. She was transferred to the
intensive care unit, where she was intubated for airway

protection and required vasopressors for blood pressure
support. Imaging of the neuroaxis failed to demonstrate any
interval changes. CSF analysis revealed an elevated IgG index
and the presence of unmatched oligoclonal bands. Once the
patient improved and stabilized, she was discharged to acute
rehabilitation. While on the rehabilitation service, she developed severe weakness in the upper and lower extremities
bilaterally that progressed to the point of exhibiting only trace
movements in the upper extremities, paraplegia, and urinary
retention.
Given the severity of deterioration, the patient was treated
with IV methylprednisolone and a course of plasma exchange.
Repeat imaging of the spinal cord now demonstrated a longitudinally extensive pattern of conﬂuent hyperintensity with
peripheral enhancement and marked edema that spanned
from the cervicomedullary junction to the upper thoracic
spinal cord (Figure 4). Serum testing by cell-based assay
yielded a positive AQP4 IgG at a titer of 1:2,560, and a diagnosis of neuromyelitis optica spectrum disorder (NMOSD)
was conﬁrmed. Siponimod was discontinued while ocrelizumab, a CD20 monoclonal antibody, was initiated.
The patient currently has only trace movements in her lower
extremities with limited antigravity movements in her upper
extremities. She requires an indwelling Foley catheter and has
signiﬁcant spasticity.

Figure 3 May 2020 Brain MRI

T1 postcontrast axial images showing multiple
ovoid-enhancing lesions (A) in the right frontal
white matter anterior to the lateral ventricle and in
the deep posterior frontal white matter (arrows),
(B) in the right periventricular region (arrow), and
(C) a punctate enhancing lesion in the parasagittal
region.
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Figure 4 July 2020 Cervical and Thoracic Cord MRI

(A) Sagittal short tau inversion recovery
showing a longitudinally extensive myelitis lesion from the cervicomedullary
junction to the upper thoracic spine
(arrow). (B) Sagittal T1 postcontrast
showing ring enhancement of the lesion (arrow). (C) Axial T1 postcontrast
showing multifocal regions of both
leptomeningeal and intramedullary
contrast enhancement, which appears
to involve both the dorsal columns and
the lateral corticospinal tract systems,
in keeping with the patient’s clinical
features of hypesthetic quadriparesis
(arrow).

Diﬀerential
Diagnostic Considerations
This case raises 2 intriguing possibilities: The ﬁrst is that our
patient was originally misdiagnosed with RRMS and followed
an atypical NMOSD course until she presented with cervicothoracic myelitis. An alternative hypothesis is that she developed 2 distinctive neuroinﬂammatory disorders in a
temporal sequence, namely the onset of MS at 18 followed by
the development of NMOSD at 57.
We will ﬁrst discuss perhaps the more controversial hypothesis: the prospect that our patient’s presentation represented
manifestations of NMOSD from the very start of her complex
clinical course. This would render the original label of RRMS,
the initial working diagnosis, as fundamentally incorrect.
Based on the disease characteristics associated with the formulation of her working diagnosis, is there any evidence that
an early misdiagnosis could have been avoided?
First, it is known that a minority of patients with NMOSD
can, in fact, exhibit short-segment spinal cord lesions that are
indistinguishable from the so-called classic skip lesions associated with MS.1 Furthermore, such patients may also have
brain lesions that appear consistent with MS.2 Studies have
shown that 60% of patients with NMOSD accumulate white
matter lesions and that as many as 16% fulﬁll the Barkhof MRI
criteria for MS.2,3
A misdiagnosis of MS could explain a lack of response to
escalation of MS DMTs, while the patient’s previous stability
on glatiramer may have been due to a protracted NMOSD
remission, which can be a characteristic of the disorder.4 In
addition, it is possible that our patient’s clinical deterioration
was precipitated by the transition in DMT from glatiramer
acetate to siponimod, as acute inﬂammatory activity associated with S-1-P modulator treatment has been documented in
NMOSD.3,5,6
The alternate hypothesis for consideration is that the patient
developed 2 distinct neuroinﬂammatory conditions occurring
4

in a temporal sequence. Although her initial presentation of
partial myelitis and a brainstem syndrome can occur in both
MS and NMOSD, the near-complete recovery of such syndromes with corticosteroids is highly reminiscent of, albeit
not speciﬁc for, MS. Our patient was well controlled without
evidence of disease activity on interferon beta-1a for nearly 30
years. Subsequently, a new exacerbation prompted a transition in DMT to glatiramer acetate, which provided another
decade of disease-free remission.
Radiographically, brain imaging studies revealed enhancing
and nonenhancing brain lesions, with features highly characteristic for MS including ovoids, periventricular hyperintensities, Dawson ﬁngers, and cerebral atrophy. Spinal cord
imaging performed early in the disease course exhibited
multifocal and discontinuous short-segment skip lesions, in
keeping with the diagnostic criteria of deﬁnite MS.5 Furthermore, CSF oligoclonal bands (as present in our patient)
are identiﬁed in ;85% of patients with MS, but in only ;15%
of patients with NMOSD.3,5
The clinical course in our patient prior to 2019 included the
documented transition from relapsing-remitting to SPMS.
Development of progressive disability years after diagnostic
conﬁrmation and treatment of RRMS, is characteristic of
SPMS, and is not an established feature of NMOSD.3,6
However, by mid-late 2019, our patient began to exhibit a
marked escalation in both clinical and radiographic disease
activity, including an episode of longitudinally extensive
transverse myelitis (more than 30 years after the initial presentation), an observation that is highly atypical for MS.

Final Diagnostic Conclusions
Taken together with the highly characteristic lesions on brain
imaging investigations (e.g., Dawson ﬁngers, ovoids, periventricular lesions, and typical enhancements as demonstrated in both Figures 2 and 3), spinal cord skip lesions, and
the absence of antecedent syndromes characteristic for and
also part of the rigorous diagnostic criteria for NMOSD (e.g.,
longitudinally extensive myelitis, optic neuritis, area postrema

Neurology: Neuroimmunology & Neuroinflammation | Volume 10, Number 1 | January 2023

Neurology.org/NN

syndrome, or diencephalic syndrome), we believe that based on
the evidence available, our patient’s initial disorder of CNS inﬂammation was more compatible with MS than with NMOSD.
Her presentation at our center decades into her disease course,
with a longitudinally extensive transverse myelitis and the presence of AQP4 antibodies, supports the development of yet a
second neuroinﬂammatory disorder, NMOSD.
A study investigated a large cohort of patients with MS for the
presence of aquaporin-4 antibodies in serum samples and
found that the rate of misdiagnosis of NMOSD as MS was
very rare, less than 1%.7 Unfortunately, testing for AQP4
antibodies was not available at the time of our patient’s initial
presentation in 1981 and would not be widely available until
some 25 years later.

Discussion
MS and NMOSD are separate diseases. MS is thought to result
from an autoimmune attack targeting proteins expressed by
myelin-producing oligodendrocytes. Alternately, NMOSD, a
humoral autoimmune disease, was distinguished as a separate
disease in 2004, with AQP4 identiﬁed as the target for the
pathogenic antibody in 2005, long after the inception of our
patient’s disorder in 1981 (Figure 1).8,9 Evidence is also now
well established to genetically diﬀerentiate the predilection of
these 2 disorders. Speciﬁcally, MS is associated with the HLADR2 (DRB1*1501) and typically presents early in life (from
adolescence to middle age), whereas NMOSD has been shown
to be associated with HLA-DR17 (DRB1*0301) and can present at any age.10
There are highly salient and diﬀerentiating radiographic characteristics for MS and NMOSD and well-deﬁned and evidencebased diagnostic criteria.3,6,11-13 However, it is important to
note that patients with MS are at higher risk of developing
other autoimmune disorders, making the possibility of 2 distinct neuroinﬂammatory disorders not untenable.14,15 For instance, it is clear that these 2 disorders can manifest in complex
ways that raise diagnostic confusion, including the prospect
that the 2 conditions might occur as separate entities in a
temporally distinctive sequence. Although we cannot be certain, we believe that the analysis of the evidence available
supports the contention that our patient did have RRMS, later
transitioning into SPMS, and that she developed NMOSD in
her sixth decade of life.
Our case report is instructive in that it emphasizes a crucial and
salient principle in clinical practice. Speciﬁcally, the neurologist
must remain vigilant and committed to periodically revisit a
fundamental tenet in neurologic diagnosis; “does the ‘working
diagnosis’ still work?” In our patient, answering the question
with precision as to whether the working diagnosis of MS
remained valid in the context of a potentially transformational
clinical syndrome, longitudinally extensive transverse myelitis,
required a well-codiﬁed, objective (now including the
Neurology.org/NN

utilization of a highly sensitive and speciﬁc molecular diagnostic
tool; the cell-based assay performed on serum for the identiﬁcation of the AQP4 autoantibody), and a systematic surveillance plan for disease monitoring in conjunction with the
interpretation of treatment response characteristics.
At least with respect to the new syndrome, the presence of the
AQP4 antibody rendered the original diagnosis of MS no
longer tenable, or that a second condition in the form of
NMOSD, evolved in conjunction with, and temporally after
the ﬁrst (i.e., MS). Modiﬁcation of the working diagnosis (es)
was indeed tantamount so that an alternate and more appropriate treatment strategy could be formulated, one that
provided potential eﬃcacy for one and/or both conditions.
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